Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment

WSJAug 8 08:24 ET

Express News | Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024

BenzingaAug 8 07:15 ET

Express News | Aldeyra: No Safety Signals Observed in Clinical Trial, and Reproxalap Was Observed to Be Well Tolerated

ReutersAug 8 07:00 ET

Express News | Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending

BenzingaAug 8 06:55 ET

Buy Rating on Aldeyra Therapeutics Backed by Strong Drug Pipeline and Lead Candidate's Market Potential

TipRanksAug 7 01:28 ET · Ratings

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results From the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Aldeyra TherapeuticsAug 7 00:00 ET